Answers are grounded in this paper and cite their sources.
Amyloid-β (Aβ) plaques and neurofibrillary tangles made of hyperphosphorylated tau protein are the two main indicators of Alzheimer's disease (AD), a progressive neurodegenerative illness. There is currently no cure, and symptomatic treatments including newly authorized anti-amyloid immunotherapies only slightly reduce cognitive loss. There is growing evidence that mitochondrial dysfunction appears early in the pathophysiology of AD and may be a primary cause of the disease's development rather than a subsequent one. Neurodegeneration is caused by a variety of mitochondrial abnormalities, including as decreased energy production, aberrant fusion and fission dynamics, elevated reactive oxygen species (ROS), and reduced mitophagy. Furthermore, mitochondrial failure is directly linked to metabolic problems such as brain insulin resistance, dysregulated lipid metabolism, and glucose hypometabolism. According to recent research, dysbiosis of the gut microbiota may exacerbate AD pathogenesis by causing neuroinflammation and metabolic abnormalities via the gut-brain axis. Restoring neuronal energy homeostasis and changing the course of illness may be possible by interventions that target these metabolic and mitochondrial pathways as well as gut bacteria.
No takes yet. Share an insight, caveat, or question.
Kumari et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: